Finally, when miR-22 mimic was administrated after bleomycin challenge in the fibrosis mouse model, the collagen content in the lungs and the α-SMA expression were attenuated too, suggesting that exosomal miR-22 could be a therapeutic agent for the treatment of IPF [164]. Here, ACTA1 is linked to fibrosis.